UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1387-4
Program Prior Authorization/Notification
Medication Pyrukynd® (mitapivat)
P&T Approval Date 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Pyrukynd® (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic
anemia in adults with pyruvate kinase (PK) deficiency.
2. Coverage Criteriaa:
A. Initial Authorization
1. Pyrukynd will be approved based on both of the following criteria:
a. Diagnosis of pyruvate kinase (PK) deficiency
-AND-
b. Used for the treatment of hemolytic anemia
Authorization will be issued for 12 months.
B. Reauthorization
1. Pyrukynd will be approved based on one of the following criteria:
a. Documentation of positive clinical response to Pyrukynd therapy
Authorization will be issued for 12 months.
-OR-
b. Documentation does not provide evidence of positive clinical response to Pyrukynd
therapy, allow for dose titration with discontinuation of therapy
Authorization will be issued for 4 weeks.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Pyrukynd [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc.; February
2022.
Program Prior Authorization/Notification - Pyrukynd® (mitapivat)
Change Control
5/2022 New program
5/2023 Annual review. Added state mandate footnote.
5/2024 Annual review. Updated initial criteria approval to 12 months.
5/2025 Annual review. No changes to coverage criteria.
© 2025 UnitedHealthcare Services Inc.
2